MOLECULAR DETERMINANTS OF OUTCOMES WITH PEMBROLIZUMAB VS PACLITAXEL IN PATIENTS WITH GASTROESOPHAGEAL ADENOCARCINOMA

In this exploratory analysis of KEYNOTE-061, the authors demonstrated a strong association between tissue tumor mutational burden (tTMB) and efficacy of second-line pembrolizumab in patients with gastric and gastroesophageal cancer, suggesting that tTMB is an independent predictor beyond PD-L1 status. There was a low correlation between whole-exome sequencing (WES)-tTMB and the PD-L1 combined positive score. WES-tTMB was associated with outcomes among pembrolizumab-treated patients after excluding known MSI-H tumors.

Download here